Chemotherapy-based gonadotoxicity risk evaluation as a predictor of reproductive outcomes in post-pubertal patients following ovarian tissue cryopreservation

Table 1 Basic characteristics of cancer survivors who responded and filled the follow-up questionnaire (n = 77)

Parameter
Age at OTCP (years)	23.7 ± 6.3
Type of malignancy
Lymphoma	37/77 (48.1%)
Leukemia	9/77 (11.7%)
Benign hematologic	4/77 (5.2%)
Breast cancer	8/77 (10.4%)
Sarcoma	10/77 (13.0%)
Carcinoma	5/77 (6.5%)
Other^a	4/77 (5.2%)
GnRHa during chemotherapy	10/77 (13.0%)
Chemotherapy prior to OTCP	21/77 (27.3%)
Risk for chemotherapy induced gonadotoxicity^b
Low risk	18/77 (23.4%)
Moderate risk	22/77 (28.6%)
High risk	37/77 (48.1%)

Data are given as n(%) or mean ± SD
OTCP, ovarian tissue cryopreservation; GnRHa, Gonadotropin releasing hormone agonist
^aOther tumors included blastomas, central nervous system and neuro-endocrine tumors
^bGonadotoxicity risk was determined by the following factors: (1) Type of chemotherapy used, specifically the inclusion of alkylating agents in the regimen, (2) The cumulative dose of alkylating agents and the alkylator equivalent score and (3) Radiation therapy to the pelvis, abdomen, cranium or total body irradiation

ISSN: 1472-6874